Please wait while we load the requested 10-Q report or click the link below:
For Investors: Rebecca Peterson, (781) 609-6378
For Media: Jennifer Snyder, (781) 609-6166
|▪||Quarterly revenues of $42.3 million, driven by strong manufacturing and royalty revenues from RISPERDAL® CONSTA®. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen-Cilag (Janssen) were approximately $356 million, an increase of 3.4 percent on an operational basis year-over-year, and are based on product sales in more than 70 countries.|
|▪||GAAP net loss of $13.4 million and pro forma net loss of $9.0 million.|
|▪||Strong financial position, with cash and total investments of $328.5 million, prior to redemption of all remaining non-recourse RISPERDAL CONSTA secured 7% Notes on July 1, 2010, at a total cost of approximately $46.4 million.|
|▪||Company preparing for upcoming October 12, 2010, Prescription Drug User Fee Act (PDUFA) date for VIVITROL® for opioid dependence and October 22, 2010, PDUFA date for BYDUREON for type 2 diabetes.|
|▪||Presented positive data from the pivotal phase 3 study of VIVITROL for the treatment of opioid dependence at the 2010 American Psychiatric Association Annual Meeting in New Orleans, Louisiana.|
Page 1 of 6
The following information was filed by Alkermes Inc on Thursday, August 5, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.